glp-1 and stroke glp 1 Receptor Agonists for Nondiabetic Ischemic Stroke: Compelling Biology, But Uncertain Glucagon-like peptide-1 cleavage product GLP-1(9–36)

This selection is further supported by the CV outcomes data for specific GLP-1RAs, which point to benefits in reducing the risk of MACE in at-risk individuals [16,17,18]

According to the Summary of Product Characteristics (SmPC), these include: Nausea (very common: may affect more than 1 in 10 people) Diarrhoea and constipation (very common) Vomiting and abdominal pain (very common) Decreased appetite and dyspepsia (very common) Most gastrointestinal adverse effects are mild to moderate in severity and tend to diminish over time as the body adjusts to treatment

Baum, M

Reputable doctors say its not worth the risks, and we would never recommend getting injections from a non-physician

Recommendations Pure Encapsulations recommends 12 capsules per day, in divided doses, between meals